MCID: MLR004
MIFTS: 86

Malaria

Categories: Genetic diseases, Rare diseases, Infectious diseases

Aliases & Classifications for Malaria

MalaCards integrated aliases for Malaria:

Name: Malaria 53 37 12 72 49 55 51 40 3 41 14 69
Malaria, Cerebral 53 41 69
Cerebral Malaria 12 14
Induced Malaria 12 69
Resistance to Malaria Due to G6pd Deficiency 53
Malaria, Cerebral, Susceptibility to 53
Malaria, Vivax, Protection Against 53
Malaria, Severe, Susceptibility to 53
Malaria, Cerebral, Reduced Risk of 53
Malaria, Severe, Resistance to 53
Malaria Due to G6pd Deficiency 53
Malaria, Protection Against 53
Malaria, Susceptibility to 53
Susceptibility to Malaria 28
Malaria, Resistance to 53
Malarial Encephalitis 12
Malaria Cerebral 51
Malaria, Severe 53
Cm 44

Characteristics:

Orphanet epidemiological data:

55
malaria
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 55  
Rare infectious diseases


Summaries for Malaria

OMIM : 53 Malaria, a major cause of child mortality worldwide, is caused by mosquito-borne hematoprotozoan parasites of the genus Plasmodium. Of the 4 species that infect humans, P. falciparum causes the most severe forms of malaria and is the major cause of death and disease. Although less fatal, P. malariae, P. ovale, and, in particular, P. vivax infections are major causes of morbidity. The parasite cycle involves a first stage in liver cells and a subsequent stage at erythrocytes, when malaria symptoms occur. A wide spectrum of phenotypes are observed, from asymptomatic infection to mild disease, including fever and mild anemia, to severe disease, including cerebral malaria, profound anemia, and respiratory distress. Genetic factors influence the response to infection, as well as disease progression and severity. Malaria is the strongest known selective pressure in the recent history of the human genome, and it is the evolutionary driving force behind sickle-cell disease (603903), thalassemia (see 141800), glucose-6-phosphatase deficiency (300908), and other erythrocyte defects that together constitute the most common mendelian diseases of humans (Kwiatkowski, 2005; Campino et al., 2006). (611162)

MalaCards based summary : Malaria, also known as malaria, cerebral, is related to plasmodium falciparum malaria and plasmodium vivax malaria, and has symptoms including myalgia, fever and headache. An important gene associated with Malaria is CD36 (CD36 Molecule), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Artesunate and Mefloquine have been mentioned in the context of this disorder. Affiliated tissues include testes, t cells and brain, and related phenotypes are hematopoietic system and cardiovascular system

NIH Rare Diseases : 49 Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. Infection with malaria parasites may result in a wide variety of symptoms, ranging from absent or very mild symptoms to severe disease and even death. People who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. In general, malaria is a curable disease if diagnosed and treated promptly and correctly. Treatment depends on many factors including disease severity, the species of malaria parasite causing the infection and the part of the world in which the infection was acquired. Last updated: 5/12/2011

MedlinePlus : 40 Malaria is a serious disease caused by a parasite. You get it when an infected mosquito bites you. Malaria is a major cause of death worldwide, but it is almost wiped out in the United States. The disease is mostly a problem in developing countries with warm climates. If you travel to these countries, you are at risk. There are four different types of malaria caused by four related parasites. The most deadly type occurs in Africa south of the Sahara Desert. Malaria symptoms include chills, flu-like symptoms, fever, vomiting, diarrhea, and jaundice. A blood test can diagnose it. It can be life-threatening. However, you can treat malaria with drugs. The type of drug depends on which kind of malaria you have and where you were infected. Malaria can be prevented. When traveling to areas where malaria is found See your doctor for medicines that protect you Wear insect repellent with DEET Cover up Sleep under mosquito netting Centers for Disease Control and Prevention

CDC : 3 Malaria is a mosquito-borne disease caused by a parasite. People with malaria often experience fever, chills, and flu-like illness. Left untreated, they may develop severe complications and die. In 2016 an estimated 216 million cases of malaria occurred worldwide and 445,000 people died, mostly children in the African Region. About 1,700 cases of malaria are diagnosed in the United States each year. The vast majority of cases in the United States are in travelers and immigrants returning from countries where malaria transmission occurs, many from sub-Saharan Africa and South Asia.

Disease Ontology : 12 A parasitic protozoa infectious disease characterized as a vector-borne infectious disease caused by the presence of protozoan parasites of the genus Plasmodium in the red blood cells, transmitted from an infected to an uninfected individual by the bite of anopheline mosquitoes, and characterized by periodic attacks of chills and fever that coincide with mass destruction of blood cells and the release of toxic substances by the parasite at the end of each reproductive cycle.

Wikipedia : 72 Malaria is a mosquito-borne infectious disease affecting humans and other animals caused by parasitic... more...

Related Diseases for Malaria

Diseases related to Malaria via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 488)
# Related Disease Score Top Affiliating Genes
1 plasmodium falciparum malaria 35.6 CD36 CR1 FCGR2A G6PD HBB HP
2 plasmodium vivax malaria 35.4 ACKR1 G6PD ICAM1 IFNG IL10 TNF
3 schistosomiasis 33.2 IFNG IL10 TNF
4 filariasis 31.9 IFNG IL10 TLR9 TNF
5 leishmaniasis 31.8 IFNG IL10 NOS2 TLR9 TNF
6 trypanosomiasis 31.8 HP ICAM1 IFNG IL10 TLR9 TNF
7 glucosephosphate dehydrogenase deficiency 31.6 G6PD HBB HP
8 sleeping sickness 31.6 HP IL10 NOS2
9 hemolytic anemia 31.4 G6PD HBB HP SLC4A1
10 mycobacterium tuberculosis 1 31.4 IFNG IL10 TLR9 TNF
11 meningitis 31.4 FCGR2A IFNG IL10 TLR9 TNF
12 visceral leishmaniasis 31.3 IFNG IL10 NOS2 TLR9 TNF
13 parasitic helminthiasis infectious disease 31.3 IL10 TLR9 TNF
14 chagas disease 31.3 IFNG IL10 NOS2 TNF
15 toxoplasmosis 31.2 IFNG IL10 TLR9 TNF
16 systemic lupus erythematosus 31.2 CR1 FCGR2A FCGR2B ICAM1 IFNG IL10
17 leprosy 3 31.2 IFNG IL10 TNF
18 alpha-thalassemia 31.1 G6PD HBB HP
19 hemophagocytic lymphohistiocytosis 31.1 CR1 IFNG IL10 TNF
20 hemorrhagic fever 31.1 IFNG IL10 TNF
21 sickle cell anemia 31.0 G6PD HBB TNF
22 pulmonary edema 31.0 ICAM1 IL10 TNF
23 dengue hemorrhagic fever 31.0 FCGR2A IFNG IL10 TNF
24 bacterial meningitis 31.0 IL10 TLR9 TNF
25 myocarditis 30.9 ICAM1 NOS2 TNF
26 multiple sclerosis 30.8 ICAM1 IFNG IL10 NOS2 TLR9 TNF
27 dermatitis, atopic 30.8 ICAM1 IFNG IL10 TLR9 TNF
28 coccidiosis 30.8 IFNG IL10 TLR9 TNF
29 bronchiolitis 30.7 IFNG IL10 TLR9 TNF
30 endomyocardial fibrosis 30.7 IL10 TNF
31 q fever 30.7 IFNG IL10 TNF
32 psoriasis 30.7 ICAM1 IFNG IL10 TLR9 TNF
33 echinococcosis 30.7 IFNG IL10 TNF
34 bronchiolitis obliterans 30.6 IFNG IL10 TNF
35 tropical endomyocardial fibrosis 30.6 IL10 TNF
36 acquired immunodeficiency syndrome 30.5 IFNG IL10 TNF
37 tungiasis 30.3 IL10 TNF
38 plasmodium malariae malaria 12.5
39 plasmodium ovale malaria 12.4
40 mixed malaria 12.3
41 malaria, mild 12.1
42 congenital myasthenic syndrome 11.9
43 blackwater fever 11.8
44 capillary malformation-arteriovenous malformation 11.7
45 myasthenic syndrome, congenital, 6, presynaptic 11.6
46 myasthenic syndrome, congenital, 10 11.6
47 myasthenic syndrome, congenital, 4c, associated with acetylcholine receptor deficiency 11.6
48 myasthenic syndrome, congenital, 1a, slow-channel 11.5
49 myasthenic syndrome, congenital, 5 11.5
50 myasthenic syndrome, congenital, 4a, slow-channel 11.5

Graphical network of the top 20 diseases related to Malaria:



Diseases related to Malaria

Symptoms & Phenotypes for Malaria

Clinical features from OMIM:

611162

Human phenotypes related to Malaria:

55 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myalgia 55 31 frequent (33%) Frequent (79-30%) HP:0003326
2 fever 55 31 hallmark (90%) Very frequent (99-80%) HP:0001945
3 headache 55 31 hallmark (90%) Very frequent (99-80%) HP:0002315
4 reduced consciousness/confusion 55 31 frequent (33%) Frequent (79-30%) HP:0004372
5 respiratory distress 55 31 frequent (33%) Frequent (79-30%) HP:0002098
6 nausea and vomiting 55 31 hallmark (90%) Very frequent (99-80%) HP:0002017
7 cognitive impairment 55 31 frequent (33%) Frequent (79-30%) HP:0100543
8 retinopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0000488
9 anemia 55 31 hallmark (90%) Very frequent (99-80%) HP:0001903
10 gait imbalance 55 31 frequent (33%) Frequent (79-30%) HP:0002141
11 thrombocytopenia 55 31 frequent (33%) Frequent (79-30%) HP:0001873
12 acute kidney injury 55 31 hallmark (90%) Very frequent (99-80%) HP:0001919
13 morphological abnormality of the central nervous system 55 31 hallmark (90%) Very frequent (99-80%) HP:0002011
14 elevated c-reactive protein level 55 31 hallmark (90%) Very frequent (99-80%) HP:0011227
15 hyperbilirubinemia 55 31 frequent (33%) Frequent (79-30%) HP:0002904
16 abnormality of blood and blood-forming tissues 55 Frequent (79-30%)

UMLS symptoms related to Malaria:


remittent fever, pruritus, fever, edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Malaria:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.21 TLR9 TNF CD36 CISH FCGR2A FCGR2B
2 cardiovascular system MP:0005385 10.2 CD36 FCGR2B G6PD HP ICAM1 IFNG
3 cellular MP:0005384 10.17 CD36 FCGR2B G6PD HP ICAM1 IFNG
4 homeostasis/metabolism MP:0005376 10.17 TNF ACKR1 CD36 CISH FCGR2B G6PD
5 immune system MP:0005387 10.1 ACKR1 CD36 CISH FCGR2A FCGR2B HP
6 digestive/alimentary MP:0005381 10.01 CD36 FCGR2B ICAM1 IFNG IL10 NOS2
7 mortality/aging MP:0010768 9.77 NOS2 SLC4A1 TIRAP TLR9 TNF CD36
8 liver/biliary system MP:0005370 9.7 CD36 FCGR2B HP IFNG IL10 NOS2
9 renal/urinary system MP:0005367 9.17 SLC4A1 TLR9 CD36 FCGR2B HP IFNG

Drugs & Therapeutics for Malaria

Drugs for Malaria (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 373)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Artesunate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 88495-63-0 5464098 6917864
2
Mefloquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53230-10-7 4046
3
Permethrin Approved, Investigational Phase 4,Phase 3 52645-53-1 40326
4
Primaquine Approved Phase 4,Phase 3,Phase 2,Phase 1 90-34-6 4908
5
Amodiaquine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 86-42-0 2165
6
Pyrimethamine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 58-14-0 4993
7
Sulfadoxine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2447-57-6 17134
8
Quinine Approved Phase 4,Phase 2,Phase 3,Phase 1 130-95-0 3034034 8549
9
Artemether Approved Phase 4,Phase 3,Phase 2,Phase 1 71963-77-4 68911 119380
10
Lumefantrine Approved Phase 4,Phase 3,Phase 2,Phase 1 82186-77-4 6437380
11
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
12
chloroquine Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 54-05-7 2719
13
Acetaminophen Approved Phase 4,Phase 3,Phase 2 103-90-2 1983
14
Albendazole Approved, Vet_approved Phase 4,Phase 2,Phase 3 54965-21-8 2082
15
Praziquantel Approved, Investigational, Vet_approved Phase 4,Phase 3 55268-74-1 4891
16
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 53477736 447043 55185
17
Sulfamethoxazole Approved Phase 4,Phase 3,Phase 1,Phase 2 723-46-6 5329
18
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 738-70-5 5578
19
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 154598-52-4 64139
20
Nevirapine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 129618-40-2 4463
21
Rifampin Approved Phase 4,Phase 2,Phase 1 13292-46-1 5381226 5458213
22
Atovaquone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 95233-18-4 74989
23
Proguanil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 500-92-5 4923
24
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 7439-89-6 23925
25
Ibuprofen Approved Phase 4,Phase 2 15687-27-1 3672
26
Hydroxychloroquine Approved Phase 4,Phase 3,Phase 2,Phase 1 118-42-3 3652
27
Doxycycline Approved, Investigational, Vet_approved Phase 4,Early Phase 1 564-25-0 54671203
28
Copper Approved, Investigational Phase 4,Phase 3 7440-50-8 27099
29
Hydroxocobalamin Approved Phase 4,Phase 3 13422-51-0 5460373 44475014 11953898
30
Iodine Approved, Investigational Phase 4,Phase 3 7553-56-2 807
31
Selenium Approved, Investigational, Vet_approved Phase 4,Phase 3 7782-49-2
32
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2 7440-66-6 32051 23994
33
Morphine Approved, Investigational Phase 4 57-27-2 5288826
34
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
35
Dapsone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80-08-0 2955
36
Lopinavir Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 192725-17-0 92727
37
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 155213-67-5 392622
38
Ivermectin Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 70288-86-7 46936176 6474909
39
Abacavir Approved, Investigational Phase 4,Phase 3 136470-78-5 441300 65140
40
Lamivudine Approved, Investigational Phase 4,Phase 3,Early Phase 1 134678-17-4 60825
41
Zidovudine Approved Phase 4,Phase 3,Early Phase 1 30516-87-1 35370
42
Amoxicillin Approved, Vet_approved Phase 4,Phase 3 26787-78-0 33613 2171
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
44
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
45
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 68-26-8, 11103-57-4 445354
46
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 3 68-19-9 44176380
47
Methylcobalamin Approved, Experimental, Investigational, Nutraceutical Phase 4,Phase 3 13422-55-4
48
Niacin Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1 59-67-6 938
49
Nicotinamide Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 1 98-92-0 936
50
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3 66-72-8 1050

Interventional clinical trials:

(show top 50) (show all 1139)

# Name Status NCT ID Phase Drugs
1 Malaria Elimination Pilot Study in Military Forces in Cambodia Unknown status NCT02653898 Phase 4 DHA-PIP;Primaquine;Artesunate + Mefloquine;Permethrin (Insecticide treated uniform)
2 Targeted Indoor Residual Spraying Against Malaria Unknown status NCT02556242 Phase 4
3 Optimization of Seasonal Malaria Chemoprevention (SMC) Delivery Unknown status NCT02646410 Phase 4
4 Intravenous Artesunate and Malaria Unknown status NCT01805232 Phase 4 artesunate;Quinine
5 Impact of Insecticide Resistance on Vector Control Unknown status NCT01713517 Phase 4
6 Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period Unknown status NCT01038063 Phase 4 Artemether-lumefantrine combination
7 Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria Unknown status NCT00902811 Phase 4 AM(FDC);AM(LT);AL;DP;AA(FDC)
8 Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children Unknown status NCT00540202 Phase 4 artemether-lumefantrine;Oral quinine
9 Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan Unknown status NCT01178021 Phase 4 Chloroquine;Chloroquine/Primaquine
10 The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention Unknown status NCT01697852 Phase 4
11 The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy Unknown status NCT01906788 Phase 4 Artemether Lumefantrine;Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0;Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
12 Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal Unknown status NCT00712374 Phase 4 sulfadoxine-pyrimethamine plus amodiaquine
13 Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand Unknown status NCT01662700 Phase 4 Artesunate;Chloroquine
14 Evaluating the Efficacy of Chloroquine for the Treatment of Plasmodium Vivax Infections in Central Vietnam Unknown status NCT02610686 Phase 4 Chloroquine
15 The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau Unknown status NCT00137566 Phase 4 acetaminophen (paracetamol)
16 Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate Unknown status NCT00238017 Phase 4 amodiaquine-artesunate versus amodiaquine
17 Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A Unknown status NCT01704508 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
18 P. Falciparum Resistance to Artemisinin in Vietnam Unknown status NCT02604966 Phase 4 Artesunate (AS) group;DHA - PPQ group
19 Investigation of Short Course, High Dose Primaquine Treatment for Liver Stages of Plasmodium Vivax Infection Unknown status NCT02364583 Phase 4 Primaquine
20 Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO Unknown status NCT01930331 Phase 4 artemisinin/naphthoquine;dihydroartemisinin/piperaquine phosphate
21 Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana Unknown status NCT01459146 Phase 4 Artemether-lumefantrine combination plus albendazole;Artemether-lumefantrine plus Praziquantel plus Albendazole;Albendazole plus Praziquantel
22 Assessment of Artesunate/Mefloquine in the Peruvian Amazon Unknown status NCT02084602 Phase 4 Artesunate;Mefloquine
23 Intermittent Antimalaria Treatment With SP in African Children Unknown status NCT00168948 Phase 4 Sulfadoxin (12.5) Pyrimethamine (250 mg)
24 Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania Unknown status NCT02199951 Phase 4 Dihydroartemisinin and piperaquine
25 Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan Unknown status NCT01075945 Phase 4 Dihydroartemisinin- piperaquine;artemether- lumefantrine
26 Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics Unknown status NCT01944189 Phase 4
27 Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria Unknown status NCT01636895 Phase 4 Efficacy of suphladoxine/pyrimethamine as IPTp;Efficacy of suphladoxine/pyrimethamine as IPTp
28 A Safety, Tolerability, Pharmacokinetic and Efficacy Study of Azithromycin Plus Piperaquine as Presumptive Treatment in Pregnant PNG Women Unknown status NCT02575755 Phase 4 Azithromycin plus piperaquine phosphate;Sulfadoxine-pyrimethamine
29 Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda Unknown status NCT00674921 Phase 4 cotrimoxazole;Placebo
30 Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
31 Vitamin A Supplementation With Bacille Calmette Guerin (BCG) Vaccine Unknown status NCT00168610 Phase 4 Vitamin A
32 Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts Completed NCT02536222 Phase 4
33 In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure Completed NCT02590627 Phase 4 Artemether-lumefantrine;Dihydroartemisinin-piperaquine
34 ANC & Malaria Diagnostic in Pregnancy Completed NCT01703884 Phase 4 ASAQ
35 The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level Completed NCT01907672 Phase 4
36 Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial Completed NCT00832754 Phase 4
37 Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria Completed NCT01150344 Phase 4 Malarone (atovaquone + proguanil combination);RIAMET (artemether + LUMEFANTRIN combination)
38 Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana Completed NCT01651416 Phase 4 Artemether-lumefantrine combination;Dihydroartemisinin Piperaquine combination;Amodiaquine plus sulphadoxine-pyrimethamine combination
39 Home Management of Malaria and Pneumonia Completed NCT02151578 Phase 4
40 The Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities Completed NCT00351013 Phase 4
41 The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in Children Completed NCT00550160 Phase 4 Amodiaquine plus Artesunate co-administration
42 Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers Completed NCT00301015 Phase 4
43 Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers Completed NCT02788864 Phase 4 Arterakine (DHA/piperaquine);Placebo
44 In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria Completed NCT02637128 Phase 4 artemether-lumefantrine (AL);artesunate-amodiaquine (ASAQ)
45 Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component Completed NCT00680732 Phase 4 Chloroquine (CQ);Sulphadoxyne-pyrimethamine (SP)
46 Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia Completed NCT01160809 Phase 4
47 A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®) Completed NCT01256658 Phase 4 COA566
48 Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya Completed NCT01669941 Phase 4 IPTp-SP;IPTp-DP;ISTp-DP
49 Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra Completed NCT01389557 Phase 4 Dihydroartemisinin-piperaquine with primaquine
50 Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania Completed NCT00687895 Phase 4

Search NIH Clinical Center for Malaria

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: malaria

Genetic Tests for Malaria

Genetic tests related to Malaria:

# Genetic test Affiliating Genes
1 Susceptibility to Malaria 28 ACKR1 CD36 CISH CR1 FCGR2A FCGR2B G6PD GYPA GYPB GYPC HBB ICAM1 NOS2 SLC4A1 TIRAP TNF

Anatomical Context for Malaria

MalaCards organs/tissues related to Malaria:

38
Testes, T Cells, Brain, Liver, Endothelial, Skin, Lung

Publications for Malaria

Articles related to Malaria:

(show top 50) (show all 3770)
# Title Authors Year
1
Exploring the impact of house screening intervention on entomological indices and incidence of malaria in Arba Minch town, southwest Ethiopia: A randomized control trial. ( 29452110 )
2018
2
Multiplex serology for impact evaluation of bed net distribution on burden of lymphatic filariasis and four species of human malaria in northern Mozambique. ( 29444078 )
2018
3
A Novel Piperazine-Based Drug Lead for Cryptosporidiosis from the Medicines for Malaria Venture Open Access Malaria Box. ( 29339392 )
2018
4
Prevalence of and risk factors for malaria, filariasis, and intestinal parasites as single infections or co-infections in different settlements of Gabon, Central Africa. ( 29378644 )
2018
5
Case Report: A Case of Severe Cerebral Malaria Managed with Therapeutic Hypothermia and Other Modalities for Brain Edema. ( 29405103 )
2018
6
Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. ( 29361939 )
2018
7
Doxycycline inhibits experimental cerebral malaria by reducing inflammatory immune reactions and tissue-degrading mediators. ( 29438386 )
2018
8
Posttreatment HRP2 Clearance in Patients with Uncomplicated Plasmodium falciparum Malaria. ( 29220497 )
2018
9
Epidemiological characteristics of malaria from control to elimination in Hubei Province, China, 2005-2016. ( 29448927 )
2018
10
RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype. ( 29439870 )
2018
11
Blackwater fever in a non-immune patient with Plasmodium falciparum malaria after intravenous artesunate. ( 29394389 )
2018
12
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger. ( 29370844 )
2018
13
Health insurance is important in improving maternal health service utilization in Tanzania-analysis of the 2011/2012 Tanzania HIV/AIDS and malaria indicator survey. ( 29439693 )
2018
14
Malaria, sickle cell disease, HIV and co-trimoxazole prophylaxis: an observational study. ( 29408573 )
2018
15
Improving the first-line treatment of febrile illnesses in Ghana: willingness to pay for malaria rapid diagnostic tests at licensed chemical shops in the Kintampo area. ( 29434526 )
2018
16
Chitinase-3-like 1 is a biomarker of acute kidney injury and mortality in paediatric severe malaria. ( 29448936 )
2018
17
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms. ( 29357870 )
2018
18
Case Report: Reversible Cerebral Vasoconstriction Syndrome in Cerebral Malaria. ( 29260652 )
2018
19
Diagnostic delay for imported malaria: A case of<i>Plasmodium falciparum</i>malaria misdiagnosed as common cold. ( 29340263 )
2018
20
CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. ( 29390987 )
2018
21
Treatment for Uncomplicated Plasmodium falciparum Malaria in French Soldiers Deployed in Sub-Saharan Africa: Gaps Between Policy and Field Practice. ( 29425320 )
2018
22
Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. ( 29447211 )
2018
23
Single low-dose primaquine for blocking transmission of Plasmodium falciparum malaria - a proposed model-derived age-based regimen for sub-Saharan Africa. ( 29347975 )
2018
24
Plasmodium falciparum malaria skews globin gene expression balance in in-vitro haematopoietic stem cell culture system: Its implications in malaria associated anemia. ( 29309785 )
2018
25
Protection from experimental cerebral malaria with a single intravenous or subcutaneous whole-parasite immunization. ( 29449638 )
2018
26
Efficacy of Artemether-Lumefantrine for Uncomplicated<i>Plasmodium falciparum</i>Malaria in Cruzeiro do Sul, Brazil, 2016. ( 29141762 )
2018
27
Fragment-Based Screening of a Natural Product Library against 62 Potential Malaria Drug Targets Employing Native Mass Spectrometry. ( 29436819 )
2018
28
A next-generation sequencing and bioinformatics protocol for Malaria drug Resistance marker Surveillance (MaRS). ( 29439965 )
2018
29
The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study. ( 29436349 )
2018
30
Quantification of human complement factor H binding to asexual malaria blood stages by an enzyme-linked immunosorbent assay. ( 29449098 )
2018
31
Case Report: Severe<i>Plasmodium vivax</i>Malaria Mimicking Sepsis in a Neonate. ( 29313481 )
2018
32
Promising approach to reducing Malaria transmission by ivermectin: Sporontocidal effect against Plasmodium vivax in the South American vectors Anopheles aquasalis and Anopheles darlingi. ( 29444080 )
2018
33
Protein-Specific Features Associated with Variability in Human Antibody Responses to<i>Plasmodium falciparum</i>Malaria Antigens. ( 29141757 )
2018
34
Fetal and maternal innate immunity receptors have opposing effects in severity of experimental malaria in pregnancy: Beneficial roles for fetal-derived TLR4 and IFNAR1. ( 29440369 )
2018
35
Multidrug-resistant Plasmodium falciparum malaria in the Greater Mekong subregion. ( 29398389 )
2018
36
Surveillance of Antimalarial Resistance Molecular Markers in Imported<i>Plasmodium falciparum</i>Malaria Cases in Anhui, China, 2012-2016. ( 29436339 )
2018
37
Immunization of malaria pre-exposed volunteers with PfSPZ Vaccine elicits long-lived IgM invasion-inhibitory and complement-fixing antibodies. ( 29438525 )
2018
38
CLINICAL AND IMMUNOLOGICAL PROFILES OF ANAEMIA IN CHILDREN AND ADOLESCENTS WITH PLASMODIUM VIVAX MALARIA IN THE PARA8 STATE, BRAZILIAN AMAZON. ( 29408596 )
2018
39
Malaria parasite LIMP protein regulates sporozoite gliding motility and infectivity in mosquito and mammalian hosts. ( 28525314 )
2017
40
Early treatment failure in concurrent dengue and mixed malaria species infection with suspected resistance to artemisinin combination therapy from a tertiary care center in Delhi: a case report. ( 28860870 )
2017
41
Therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria among outpatients at Shawa Robit Health Care Centre, North-East Ethiopia. ( 28300558 )
2017
42
Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana. ( 28945794 )
2017
43
TOLLIP gene variant is associated with Plasmodium vivax malaria in the Brazilian Amazon. ( 28288644 )
2017
44
Prevalence of Clinical and Subclinical<i>Plasmodium falciparum</i>and<i>Plasmodium vivax</i>Malaria in Two Remote Rural Communities on the Myanmar-China Border. ( 29016341 )
2017
45
Strong renal expression of heat shock protein 70, high mobility group box 1, inducible nitric oxide synthase, and nitrotyrosine in mice model of severe malaria. ( 28954070 )
2017
46
An erythroid-specific ATP2B4 enhancer mediates red blood cell hydration and malaria susceptibility. ( 28714864 )
2017
47
Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda. ( 28089547 )
2017
48
Turf wars: exploring splenomegaly in sickle cell disease in malaria-endemic regions. ( 28493472 )
2017
49
Safety and Efficacy of Adding a Single Low Dose of Primaquine to the Treatment of Adult Patients With Plasmodium falciparum Malaria in Senegal, to Reduce Gametocyte Carriage: A Randomized Controlled Trial. ( 28605472 )
2017
50
Improving local health workers' knowledge of malaria in the elimination phase-determinants and strategies: a cross-sectional study in rural China. ( 28526083 )
2017